Last week, the York, PA-based dental product manufacturer reported 2015 third quarter earnings of 66 cents per share on revenue of $648.9 million. Analysts surveyed by Thomson Reuters were expecting the company to report earnings of 63 cents per share on revenue of $666.95 million.
"During the third quarter, the business continued to achieve strong earnings growth despite a significant headwind from currency. We have been executing our global efficiency program and have realized improved margins well ahead of plan," DENTSPLY CEO Bret Wise said in a statement.
Credit Suisse analysts raised their fiscal 2015 earnings estimates for DENTSPLY to $2.62 from $2.60 per share and their fiscal 2016 earnings estimate to $2.80 from $2.78 per share.
Shares of DENTSPLY were up by 2.35% to $62.28 in mid-afternoon trading on Thursday.
Separately, TheStreet Ratings team rates DENTSPLY INTERNATL INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
We rate DENTSPLY INTERNATL INC (XRAY) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
You can view the full analysis from the report here: XRAY